Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development(1) | $29,145 | $19,925 |
| General and administrative(2) | 7,289 | 5,161 |
| Total operating expenses | 36,434 | 25,086 |
| Loss from operations | (36,434) | (25,086) |
| Other income (expense): | ||
| Interest income | 4,606 | 4,092 |
| Other income (expense), net | 8 | (5) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s G&A?
- Oruka Therapeutics, Inc. (ORKA) reported G&A of $7.29M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s G&A changed year-over-year?
- Oruka Therapeutics, Inc.'s G&A increased by 41.2% year-over-year, from $5.16M to $7.29M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s G&A has grown at a 40.4% compound annual growth rate (CAGR), from $5.5M to $21.41M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Oruka Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude